HRP20140729T1 - Inhibitori met aktivnosti za primjenu u cilju poveä†anja efikasnosti radioterapije - Google Patents
Inhibitori met aktivnosti za primjenu u cilju poveä†anja efikasnosti radioterapije Download PDFInfo
- Publication number
- HRP20140729T1 HRP20140729T1 HRP20140729AT HRP20140729T HRP20140729T1 HR P20140729 T1 HRP20140729 T1 HR P20140729T1 HR P20140729A T HRP20140729A T HR P20140729AT HR P20140729 T HRP20140729 T HR P20140729T HR P20140729 T1 HRP20140729 T1 HR P20140729T1
- Authority
- HR
- Croatia
- Prior art keywords
- inhibitor
- met
- met activity
- nucleotide sequence
- sequence encoding
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 31
- 238000001959 radiotherapy Methods 0.000 title claims 8
- 230000002708 enhancing effect Effects 0.000 title 1
- 230000000694 effects Effects 0.000 claims 30
- 239000002773 nucleotide Substances 0.000 claims 14
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- 108010088751 Albumins Proteins 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 101150105382 MET gene Proteins 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 230000003828 downregulation Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000009033 hematopoietic malignancy Effects 0.000 claims 1
- 210000004754 hybrid cell Anatomy 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11158861.2A EP2500036B1 (en) | 2011-03-18 | 2011-03-18 | MET inhibitors for enhancing radiotherapy efficacy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140729T1 true HRP20140729T1 (hr) | 2014-08-29 |
Family
ID=44260211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140729AT HRP20140729T1 (hr) | 2011-03-18 | 2014-07-29 | Inhibitori met aktivnosti za primjenu u cilju poveä†anja efikasnosti radioterapije |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20120237524A1 (enExample) |
| EP (1) | EP2500036B1 (enExample) |
| JP (1) | JP5671487B2 (enExample) |
| KR (1) | KR101540838B1 (enExample) |
| CN (1) | CN102688491A (enExample) |
| AU (1) | AU2012201303B2 (enExample) |
| BR (1) | BR102012006063B1 (enExample) |
| CA (1) | CA2769991C (enExample) |
| CY (1) | CY1115374T1 (enExample) |
| DK (1) | DK2500036T3 (enExample) |
| EA (1) | EA028590B1 (enExample) |
| ES (1) | ES2489475T3 (enExample) |
| HR (1) | HRP20140729T1 (enExample) |
| IL (1) | IL218293A (enExample) |
| MX (1) | MX2012003084A (enExample) |
| PL (1) | PL2500036T3 (enExample) |
| PT (1) | PT2500036E (enExample) |
| RS (1) | RS53468B (enExample) |
| SG (1) | SG184637A1 (enExample) |
| SI (1) | SI2500036T1 (enExample) |
| SM (1) | SMT201400106B (enExample) |
| ZA (1) | ZA201201992B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| IT201800009282A1 (it) * | 2018-10-09 | 2020-04-09 | Metis Prec Medicine Sb Srl | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
| CN110320365B (zh) * | 2019-07-06 | 2022-07-22 | 湖南莱拓福生物科技有限公司 | NF-κB RelA/p65蛋白位点特异性磷酸化诊断试剂盒 |
| KR20220063185A (ko) | 2019-09-16 | 2022-05-17 | 리제너론 파마슈티칼스 인코포레이티드 | 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질 |
| KR20250164828A (ko) | 2023-03-30 | 2025-11-25 | 레볼루션 메디슨즈, 인크. | Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| BRPI0407446A (pt) * | 2003-02-13 | 2006-01-31 | Pharmacia Corp | Anticorpos para c-met para o tratamento de cânceres |
| RS53476B (sr) * | 2003-07-18 | 2014-12-31 | Amgen Fremont Inc. | Sredstva za specifično vezivanje faktora rasta hepatocita |
| HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| KR101429297B1 (ko) * | 2006-02-06 | 2014-08-12 | 메테레시스 트랜스레이셔날 리서치 에스.에이. | 종양 치료를 위한 항-Ｍｅｔ 단클론 항체, 이의 단편과벡터 및 상응하는 산물 |
| EP2019116A1 (en) * | 2007-07-26 | 2009-01-28 | Helmholtz-Zentrum für Infektionsforschung GmbH | Inhibitor of the met-receptor and its use |
-
2011
- 2011-03-18 SI SI201130217T patent/SI2500036T1/sl unknown
- 2011-03-18 PL PL11158861T patent/PL2500036T3/pl unknown
- 2011-03-18 ES ES11158861.2T patent/ES2489475T3/es active Active
- 2011-03-18 PT PT111588612T patent/PT2500036E/pt unknown
- 2011-03-18 RS RS20140404A patent/RS53468B/sr unknown
- 2011-03-18 EP EP11158861.2A patent/EP2500036B1/en active Active
- 2011-03-18 DK DK11158861.2T patent/DK2500036T3/da active
-
2012
- 2012-02-22 SG SG2012012514A patent/SG184637A1/en unknown
- 2012-02-23 IL IL218293A patent/IL218293A/en active IP Right Grant
- 2012-02-24 JP JP2012039193A patent/JP5671487B2/ja active Active
- 2012-03-01 CA CA2769991A patent/CA2769991C/en active Active
- 2012-03-02 AU AU2012201303A patent/AU2012201303B2/en active Active
- 2012-03-13 MX MX2012003084A patent/MX2012003084A/es active IP Right Grant
- 2012-03-13 KR KR1020120025311A patent/KR101540838B1/ko active Active
- 2012-03-16 BR BR102012006063-9A patent/BR102012006063B1/pt active IP Right Grant
- 2012-03-16 ZA ZA2012/01992A patent/ZA201201992B/en unknown
- 2012-03-16 CN CN2012100803665A patent/CN102688491A/zh active Pending
- 2012-03-16 EA EA201200329A patent/EA028590B1/ru not_active IP Right Cessation
- 2012-03-19 US US13/423,830 patent/US20120237524A1/en not_active Abandoned
-
2014
- 2014-07-24 CY CY20141100561T patent/CY1115374T1/el unknown
- 2014-07-29 HR HRP20140729AT patent/HRP20140729T1/hr unknown
- 2014-07-31 SM SM201400106T patent/SMT201400106B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102688491A (zh) | 2012-09-26 |
| SMT201400106B (it) | 2014-11-10 |
| SG184637A1 (en) | 2012-10-30 |
| BR102012006063A8 (pt) | 2022-11-08 |
| JP5671487B2 (ja) | 2015-02-18 |
| KR101540838B1 (ko) | 2015-08-06 |
| RS53468B (sr) | 2014-12-31 |
| CA2769991A1 (en) | 2012-09-18 |
| EP2500036B1 (en) | 2014-05-07 |
| ES2489475T3 (es) | 2014-09-02 |
| DK2500036T3 (da) | 2014-08-04 |
| EP2500036A1 (en) | 2012-09-19 |
| EA201200329A2 (ru) | 2012-09-28 |
| HK1174539A1 (en) | 2013-06-14 |
| IL218293A (en) | 2016-06-30 |
| AU2012201303A1 (en) | 2012-10-04 |
| PL2500036T3 (pl) | 2014-10-31 |
| EA028590B1 (ru) | 2017-12-29 |
| BR102012006063A2 (pt) | 2021-11-16 |
| MX2012003084A (es) | 2012-09-17 |
| CY1115374T1 (el) | 2017-01-04 |
| IL218293A0 (en) | 2012-07-31 |
| SI2500036T1 (sl) | 2014-09-30 |
| AU2012201303B2 (en) | 2013-11-07 |
| JP2012196206A (ja) | 2012-10-18 |
| KR20120106582A (ko) | 2012-09-26 |
| PT2500036E (pt) | 2014-08-25 |
| US20120237524A1 (en) | 2012-09-20 |
| CA2769991C (en) | 2018-05-15 |
| BR102012006063B1 (pt) | 2023-03-07 |
| EA201200329A3 (ru) | 2013-01-30 |
| ZA201201992B (en) | 2015-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140729T1 (hr) | Inhibitori met aktivnosti za primjenu u cilju poveä†anja efikasnosti radioterapije | |
| JP2012196206A5 (enExample) | ||
| Yeini et al. | Targeting glioblastoma: Advances in drug delivery and novel therapeutic approaches | |
| Stuckey et al. | TRAIL on trial: preclinical advances in cancer therapy | |
| ES2808153T3 (es) | Terapia de combinación para tratamiento de enfermedad | |
| US11679082B2 (en) | Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor | |
| ES2727154T3 (es) | Combinación | |
| ES2765949T3 (es) | Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer | |
| ES2622958T3 (es) | ARNip frente a Cbl-b combinado con citocinas e interferones en el tratamiento de cáncer | |
| Mishan et al. | CXCR4 and CCR7: Two eligible targets in targeted cancer therapy | |
| JP2013506411A5 (enExample) | ||
| RU2015139969A (ru) | Комбинация вакцинации и ингибирования пути pd-1 | |
| JP2019504105A5 (enExample) | ||
| CN107223057A (zh) | 布罗莫结构域抑制剂作为癌症免疫治疗的补充剂 | |
| WO2012094653A4 (en) | Compositions and methods for macromolecular drug delivery | |
| JP2014509841A5 (enExample) | ||
| CN108392633A (zh) | Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用 | |
| WO2023056202A2 (en) | Compositions and methods for enhanced protein production | |
| CN104684552A (zh) | 组合及其用途 | |
| WO2006108474A3 (en) | Use of a galectin-1-trageted rnai-based approach for the treatment of cancer | |
| CN111615518B (zh) | 阻断emt途径并克服癌干细胞的il8 | |
| Wang et al. | Spatiotemporal Nano‐Regulator Unleashes Anti‐Tumor Immunity by Overcoming Dendritic Cell Tolerance and T Cell Exhaustion in Tumor‐Draining Lymph Nodes | |
| US11512141B2 (en) | Fibrinogen-like protein 2 (FGL2) monoclonal antibodies and their use in cancer detection and treatment | |
| WO2016066671A1 (en) | Method for treating resistant cancers using progastrin inhibitors | |
| Liu et al. | Cancer biotherapy: review and prospect |